Clinical aspects of inflammatory breast cancer.
Inflammatory breast cancer (IBC), accounting for 1-5% of all breast cancers, is the most aggressive form of breast cancer. Its biologically aggressive nature is identified by the rapid time to progression, its tendency to affect younger women, the high proportion of local and distant metastases present at diagnosis, and lower overall survival despite the use of multimodality therapy. With epidemiologic and molecular evidence now suggesting that IBC may represent a distinct disease entity rather than part of the spectrum of locally advanced breast cancer (LABC), accurate differentiation of these two disease processes has never been more crucial to ensure appropriate treatment. This review addresses the historical milestones and clinical characteristics involved in the differentiation of IBC and briefly discusses the emerging molecular data that may facilitate the distinction of IBC from LABC.
Walshe
Janice M
JM
Breast Cancer Section, Medical Oncology Branch, Centre for Cancer Research, National Cancer Institute, National Institute of Health, MD 20889, USA.
Swain
Sandra M
SM
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D000328:Adult; D017677:Age Distribution; D000368:Aged; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015994:Incidence; D008875:Middle Aged; D011379:Prognosis; D035583:Rare Diseases; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology